Olaf Stuve
Dallas VA Medical Center · University of Texas Southwestern Medical Center
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Olaf Stuve as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:45 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT04244630 · Mitochondrial Capacity Boost in ALS (MICABO-ALS) TrialDallas VA Medical Center · active not recruiting · Amyotrophic Lateral Sclerosis (ALS) · principal investigator
- Ph4NCT04178005 · Cladribine Tablets After Treatment With Natalizumab (CLADRINA)University of Texas Southwestern Medical Center · active not recruiting · Multiple Sclerosis · principal investigator
- Ph4NCT03135249 · Sequential Natalizumab - Alemtuzumab Therapy in Patients With Relapsing Forms of Multiple SclerosisUniversity of Texas Southwestern Medical Center · completed · Multiple Sclerosis (MS) · principal investigator
- Ph2NCT01710228 · Alternative Treatment Paradigm for Natalizumab TrialUniversity of Texas Southwestern Medical Center · withdrawn · Multiple Sclerosis (MS) · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:45 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Defining the role of CD11c+CD88+CD317+ myeloid cells as mediators of CNS autoimmunityI01BX005664 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · fiscal years 2022 to 2026Same name and institution; not confirmed by an ID
- Immune Checkpoint-Engineered oligodendrocytes as treatment for multiple sclerosisR56AI188482 · NIAID · UT SOUTHWESTERN MEDICAL CENTER · fiscal years 2025 · $300,000 awarded in 2025Same name and institution; not confirmed by an ID
- Determining the compartmental role of B cell subsets during CNS autoimmunityI01BX001674 · VA · VA NORTH TEXAS HEALTH CARE SYSTEM · fiscal years 2013 to 2016Same name and institution; not confirmed by an ID
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:45 UTC. The ranking covers the 200 most relevant of 14 PubMed records, and a shared surname and initials can bring in a namesake. All 14 on PubMed
- Altered CD4+/CD8+ T-cell ratios in cerebrospinal fluid of natalizumab-treated patients with multiple sclerosis.Arch Neurol · 2006244 citationsRCR 5.4
- Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.Lancet Neurol · 2013199 citationsRCR 6.7
- Decrease in the numbers of dendritic cells and CD4+ T cells in cerebral perivascular spaces due to natalizumab.Arch Neurol · 2008152 citationsRCR 3.3
- 132 citationsRCR 4.6
- 125 citationsRCR 4.6
- 119 citationsRCR 13.8
- Immunologic, clinical, and radiologic status 14 months after cessation of natalizumab therapy.Neurology · 2009106 citationsRCR 2.8
- Safety and Efficacy of Siponimod (BAF312) in Patients With Relapsing-Remitting Multiple Sclerosis: Dose-Blinded, Randomized Extension of the Phase 2 BOLD Study.JAMA Neurol · 201688 citationsRCR 3.3
- Safety and efficacy of evobrutinib in relapsing multiple sclerosis (evolutionRMS1 and evolutionRMS2): two multicentre, randomised, double-blind, active-controlled, phase 3 trials.Lancet Neurol · 202478 citationsRCR 11.0
- Memantine for cognitive impairment in multiple sclerosis: a randomized placebo-controlled trial.Mult Scler · 201067 citationsRCR 2.1